Already Registered? Sign in to continue reading.

New to Pink Sheet? Request a free trial today!

Free Trial

Announcement: We will be performing site maintenance from Friday, 20 October 8:30 pm EDT (1:30 am BST) to Saturday, 21 October 5 am EDT (10 am BST).
During this period you may experience site instability as we implement an upgraded sign-in process and the My View tool.
For more information about these enhancements, visit our launch portal.

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

This article was originally published in The Pink Sheet Daily

19 Aug 2015

Executive Summary

With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Request a free trial today!

Free Trial

Table
View full table

Topics

United States

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078823

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078823

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Description text

Thanks, we've sent a link to reset your password

Forgot your password?

Enter the email address associated with your account and an email will be sent to you to reset your password.

Please enter a valid email address.

Unfortunately we've not been able to process this request.

Need help?

Email: clientservices@pharmamedtechbi.com
Phone: (US Toll-Free): +1 888-670-8900; (US Collect): +1 908-547-2200
Phone (UK & Europe): +44 (20) 337 73737
Phone (APAC): +61 2 8705 6907

Thanks, we've sent a link to reset your password

Forgot your password?

Enter the email address associated with your account and an email will be sent to you to reset your password.

Please enter a valid email address.

Unfortunately we've not been able to process this request.

Need help?

Email: clientservices@pharmamedtechbi.com
Phone: (US Toll-Free): +1 888-670-8900; (US Collect): +1 908-547-2200
Phone (UK & Europe): +44 (20) 337 73737
Phone (APAC): +61 2 8705 6907

Forgot your password?

Forgot your password?

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

Executive Summary

Forgot your password?

Related Content

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support

Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher

Topics

Related Companies

Related Deals

What to read next

You must sign in to use this functionality

Forgot your password?

Authentication.SignIn.HeadSignInHeader

Forgot your password?

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert

Forgot your password?

Forgot your password?